AviaraDx Inc., a leader in molecular cancer profiling, is focused on developing and commercializing molecular diagnostic technologies and high value assays for personalized medicine in cancer treatment. The company is targeting the oncology market with three first-in-class molecular cancer profiling technologies: Molecular Cancer Classification and Identification for Cancer of the Unknown Primary, Breast Cancer Assays such as HOXB13/IL 17BR, and Drug Response Profiling Assays. AviaraDx has licensed its technologies for specific clinical indications to reference laboratories in the United States and Europe.
In September 2008, AviaraDx was acquired by bioMerieux, which has re-named the company bioTheranostics. SDL Ventures was the lead investor in this successful divestiture.